These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 32875273)

  • 21. Targeting of NMDA receptors in the treatment of major depression.
    Dang YH; Ma XC; Zhang JC; Ren Q; Wu J; Gao CG; Hashimoto K
    Curr Pharm Des; 2014; 20(32):5151-9. PubMed ID: 24410564
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ketamine for the treatment of major depressive disorder and bipolar depression: A review of the literature.
    Grady SE; Marsh TA; Tenhouse A; Klein K
    Ment Health Clin; 2017 Jan; 7(1):16-23. PubMed ID: 29955493
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ketamine for rapid reduction of suicidal ideation: a randomized controlled trial.
    Murrough JW; Soleimani L; DeWilde KE; Collins KA; Lapidus KA; Iacoviello BM; Lener M; Kautz M; Kim J; Stern JB; Price RB; Perez AM; Brallier JW; Rodriguez GJ; Goodman WK; Iosifescu DV; Charney DS
    Psychol Med; 2015 Dec; 45(16):3571-80. PubMed ID: 26266877
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Antidepressant effect of ketamine, a N-methyl-D-aspartate (NMDA) glutamate receptor antagonist, in the therapy of treatment-resistant depression].
    Gosek P; Chojnacka M; Bieńkowski P; Swiecicki Ł
    Psychiatr Pol; 2012; 46(2):283-94. PubMed ID: 23214398
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Symptomatology and predictors of antidepressant efficacy in extended responders to a single ketamine infusion.
    Pennybaker SJ; Niciu MJ; Luckenbaugh DA; Zarate CA
    J Affect Disord; 2017 Jan; 208():560-566. PubMed ID: 27839782
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical Efficacy of Ketamine for Treatment-resistant Depression.
    Bratsos S; Saleh SN
    Cureus; 2019 Jul; 11(7):e5189. PubMed ID: 31565597
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The role of ketamine in treatment-resistant depression: a systematic review.
    Serafini G; Howland RH; Rovedi F; Girardi P; Amore M
    Curr Neuropharmacol; 2014 Sep; 12(5):444-61. PubMed ID: 25426012
    [TBL] [Abstract][Full Text] [Related]  

  • 28. An assessment of the anti-fatigue effects of ketamine from a double-blind, placebo-controlled, crossover study in bipolar disorder.
    Saligan LN; Luckenbaugh DA; Slonena EE; Machado-Vieira R; Zarate CA
    J Affect Disord; 2016 Apr; 194():115-9. PubMed ID: 26807672
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ketamine's dose-related effects on anxiety symptoms in patients with treatment refractory anxiety disorders.
    Glue P; Medlicott NJ; Harland S; Neehoff S; Anderson-Fahey B; Le Nedelec M; Gray A; McNaughton N
    J Psychopharmacol; 2017 Oct; 31(10):1302-1305. PubMed ID: 28441895
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A systematic review and meta-analysis of randomized, double-blind, placebo-controlled trials of ketamine in the rapid treatment of major depressive episodes.
    McGirr A; Berlim MT; Bond DJ; Fleck MP; Yatham LN; Lam RW
    Psychol Med; 2015 Mar; 45(4):693-704. PubMed ID: 25010396
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Is off-label repeat prescription of ketamine as a rapid antidepressant safe? Controversies, ethical concerns, and legal implications.
    Zhang MW; Harris KM; Ho RC
    BMC Med Ethics; 2016 Jan; 17():4. PubMed ID: 26768892
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Emerging role of glutamate in the pathophysiology of major depressive disorder.
    Hashimoto K
    Brain Res Rev; 2009 Oct; 61(2):105-23. PubMed ID: 19481572
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Monoamine neurocircuitry in depression and strategies for new treatments.
    Hamon M; Blier P
    Prog Neuropsychopharmacol Biol Psychiatry; 2013 Aug; 45():54-63. PubMed ID: 23602950
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The role of NMDA receptor in neurobiology and treatment of major depressive disorder: Evidence from translational research.
    Amidfar M; Woelfer M; Réus GZ; Quevedo J; Walter M; Kim YK
    Prog Neuropsychopharmacol Biol Psychiatry; 2019 Aug; 94():109668. PubMed ID: 31207274
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Effect of Ketamine on Electrophysiological Connectivity in Major Depressive Disorder.
    Nugent AC; Ballard ED; Gilbert JR; Tewarie PK; Brookes MJ; Zarate CA
    Front Psychiatry; 2020; 11():519. PubMed ID: 32655423
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Glutamatergic approaches in major depressive disorder: focus on ketamine, memantine and riluzole.
    Owen RT
    Drugs Today (Barc); 2012 Jul; 48(7):469-78. PubMed ID: 22844658
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment-Resistant Major Depression: Rationale for NMDA Receptors as Targets and Nitrous Oxide as Therapy.
    Zorumski CF; Nagele P; Mennerick S; Conway CR
    Front Psychiatry; 2015; 6():172. PubMed ID: 26696909
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Paroxetine: an update of its use in psychiatric disorders in adults.
    Wagstaff AJ; Cheer SM; Matheson AJ; Ormrod D; Goa KL
    Drugs; 2002; 62(4):655-703. PubMed ID: 11893234
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Major Depressive Disorder and Kappa Opioid Receptor Antagonists.
    Li W; Sun H; Chen H; Yang X; Xiao L; Liu R; Shao L; Qiu Z
    Transl Perioper Pain Med; 2016; 1(2):4-16. PubMed ID: 27213169
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Modulation of the activity of
    Vasilescu AN; Schweinfurth N; Borgwardt S; Gass P; Lang UE; Inta D; Eckart S
    Neuropsychiatr Dis Treat; 2017; 13():973-980. PubMed ID: 28408831
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.